Loxo Oncology (LOXO) Tops Q1 EPS by 60c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Brazil’s Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Oil settles lower on peace hopes, Saudi attacks limit losses
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
Loxo Oncology (LOXO) PT Raised to $145 at Stifel; All Eyes on LOXO-292 Data at ASCO
May 9, 2018 6:17 AM EDTStifel raised its price target on Loxo Oncology (NASDAQ: LOXO) to $145.00 (from $135.00) while maintaining a Buy rating.
Analyst Stephen Willey commented, "We continue to like LOXO shares into next months (June 2) presentation of P1 LOXO-292 data at the annual ASCO meeting as we... More



